Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age (DYS FUTURS UHR)

Childhood Learning and Executive Function Disorders and Risk of Psychosis in the Adulthood

The primary objective of the study aims to study transition toward schizophrenia in patients with learning disorders, and to compare the risk between patients with specific learning disorders, and patients with complexed learning disorders (by two types: patients with other neuro-developmental disorders including executive function disorders, and patients with anxiety).

Study Overview

• Status: Completed
• Conditions: Schizophrenia; Learning Disorders; Executive Function Disorders
• Intervention / Treatment: Diagnostic test: Standardised semi-structured talk; Diagnostic test: Autistic spectre disorder screening; Diagnostic test: Anxiety measuring

Detailed Description

As secondary objectives, the study aims to:

• argue the clinical predicted markers (neuropsychological) transition toward psychosis.
• test the feasibility and the acceptability of a early diagnosis for a potential applicable guidance for different referent centers of learning in French territory.
• have a better classification of patients with learning disorders in order to target a prospective primary prevention of risk of psychosis via the questionnaires (AQ of Baron-Cohen: Autism-spectrum quotient auto-questionnaire; Inventory of Beck Anxiety Inventory, auto-questionnaire for panic disorder and general anxiety; Liebowitz Social Anxiety Scale).
• improve identification of the early signs and the early emerging psychological diseases intervention management (schizophrenia).
• Psychic disability: prevent and reduce non-seeking care and accompaniment situations, and risk of rupture of care.
• permitting better care of psychosocial rehabilitation with cognitive evaluation.

This study will be conducted in Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP, in France.

• Study Type: Observational
• Enrollment (Actual): 20

Contacts and Locations

Study Locations

• France
  • Garches, France, 92380
    • Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 30 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients between 15 and 30 years, suffering learning disorders complicated with two orders: with other neuro-developmental, or with anxiety (vs specific: comparator group).

Description

Inclusion Criteria:

• Patients born between 1990 and 2005, have been cared by Dr Schlumberger in 2014 in the center of language and learning disorders at Raymond Poincaré hospital;
• With severe learning disorders: deficiency in school work, need at least one medical appointment and long-term rehabilitation in the center of language and learning disorders at Raymond Poincaré hospital;
• Affiliated to a social protection schema;
• Written informed consent signed.

Exclusion Criteria:

• Absence of learning disorder;
• Intellectual deficiency;
• Epilepsia;
• Patients who will performed follow-up at Chartres city;
• Patients under guardianship or curatorship;
• Foreign patients under AME schema, a medical help from the state in France.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Comparator group; Specific learning disorders group	Diagnostic test: Standardised semi-structured talk; Comprehensive assessment of at-risk mental states (CAARMS) will be used.; Diagnostic test: Autistic spectre disorder screening; Autism-spectrum quotient (AQ) auto-questionnaire will be used.; Diagnostic test: Anxiety measuring; An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
neuro-developmental complexed group; Group of neuro-developmental complexe of learning	Diagnostic test: Standardised semi-structured talk; Comprehensive assessment of at-risk mental states (CAARMS) will be used.; Diagnostic test: Autistic spectre disorder screening; Autism-spectrum quotient (AQ) auto-questionnaire will be used.; Diagnostic test: Anxiety measuring; An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
Complexed with anxiety; Disorders in learning with anxiety	Diagnostic test: Standardised semi-structured talk; Comprehensive assessment of at-risk mental states (CAARMS) will be used.; Diagnostic test: Autistic spectre disorder screening; Autism-spectrum quotient (AQ) auto-questionnaire will be used.; Diagnostic test: Anxiety measuring; An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Semi-structured interview	Assessement with Comprehensive Assessment of At-Risk Mental States (CAARMS) during 6 to 90 minutes at the center of Raymond Poincaré hospital. The unique collection during the interview, quotation of each patient will be given from the assessement. There will be 4 groups by the results: CAARMS negative subjects, vulnerable subjects, attenuated psychosis subjects and subjects with brief and limited intermittent psychotic syndrome. The further statistic comparison will be done between the 3 last groups classified with results of CAARMS.	At baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Autistic screening	Autism-spectrum quotient (AQ) auto-questionnaire will be used to evaluate difficulty in social interaction.	At baseline
Anxiety measuring	An inventory for measuring clinical anxiety: Beck Anxiety Inventory	At baseline
Social interaction difficulty evaluation	Liebowitz Social Anxiety Scale as questionnaire	At baseline

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Emilie SCHLUMBERGER, MD, Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP; Study Director: Albane Mansoux, Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP

Study record dates

Study Major Dates

• Study Start (Actual): January 28, 2020
• Primary Completion (Actual): May 29, 2020
• Study Completion (Actual): May 29, 2020

Study Registration Dates

• First Submitted: February 20, 2020
• First Submitted That Met QC Criteria: February 20, 2020
• First Posted (Actual): February 21, 2020

Study Record Updates

• Last Update Posted (Actual): August 22, 2023
• Last Update Submitted That Met QC Criteria: August 21, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: children; psychosis; learning disorders; executive function disorders; adult-age
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Schizophrenia Spectrum and Other Psychotic Disorders; Neurodevelopmental Disorders; Communication Disorders; Schizophrenia; Psychotic Disorders; Mental Disorders; Learning Disabilities
• Other Study ID Numbers: APHP191093; 2019-A02663-54 (Registry Identifier: IDRCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No